Citius Pharmaceuticals (NASDAQ:CTXR) is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.
One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal. Mino-Lok combines minocycline, EDTA and ethanol in a proprietary formulation that has completed multiple clinical trials and is undergoing regulatory review. In parallel, Citius is developing CTx001, a proprietary subcutaneous infusion platform intended to facilitate rapid, consistent delivery of protein and antibody therapies without the need for intravenous access.
Beyond its core pipeline, Citius has advanced investigational candidates in areas such as post‐surgical pancreatic fluid collections and localized dermatology applications. The company also markets Aqclarity™, a water purification and disinfection system for use in healthcare settings, including dialysis centers and surgical suites. Through ongoing collaborations and licensing agreements, Citius aims to extend its reach into both domestic and select international markets.
Leadership at Citius Pharmaceuticals is led by Founder and Chief Executive Officer John T. Elliott, who brings more than two decades of experience in pharmaceutical development and commercialization. The company’s senior management team combines expertise in clinical research, regulatory affairs and business development. As a clinical‐stage organization, Citius continues to advance its pipeline through late-stage trials and regulatory milestones with a goal of bringing novel therapies to patients in critical care settings.
